Management of Elevated AST and ALT Levels

Initial Evaluation

The American Gastroenterological Association recommends a detailed history to assess risk factors for liver disease, medication use, alcohol consumption, and comorbid conditions 2, 3
A physical examination should be performed to look for signs of chronic liver disease such as jaundice, ascites, spider angiomata, and hepatomegaly 2
Initial laboratory testing should include a complete liver panel (ALT, AST, alkaline phosphatase, GGT, total and direct bilirubin, albumin, prothrombin time) 2, 3
Viral hepatitis serologies (HAV-IgM, HBsAg, HBcIgM, HCV antibody) should be included in the initial evaluation 2, 3
Autoimmune markers such as ANA, ASMA, and immunoglobulins should be tested if autoimmune hepatitis is suspected 4, 5
An abdominal ultrasound should be performed to assess liver structure, rule out biliary obstruction, and detect fatty infiltration 2, 3

For mild elevations (ALT/AST < 5× ULN), the European Association for the Study of the Liver recommends identifying and removing potential causative agents, such as discontinuing hepatotoxic medications 1, 6
For moderate to severe elevations (ALT/AST > 5× ULN), immediate action is required, including discontinuing all potentially hepatotoxic medications and performing a more expeditious and complete diagnostic evaluation 7, 6, 2, 3

For drug-induced liver injury, the American Association for the Study of Liver Diseases recommends discontinuing the suspected causative agent 1, 7
For non-alcoholic fatty liver disease (NAFLD), lifestyle modifications such as weight loss, exercise, and dietary changes are recommended, as well as management of associated metabolic conditions (diabetes, dyslipidemia) 4, 5
For viral hepatitis, monitoring for disease progression and complications is necessary, as well as screening for hepatocellular carcinoma in chronic cases 2, 3

The American College of Gastroenterology recommends using ALT instead of AST for monitoring liver injury due to its higher hepatic specificity 1, 8
Patients with liver metastases or primary liver tumors may have higher baseline transaminase levels and require different thresholds for intervention 1, 8

The American Association for the Study of Liver Diseases recommends continuing monitoring until normalization or stabilization of liver enzymes 7, 6
Long-term follow-up is necessary for chronic liver diseases to assess progression and development of complications 2, 3

The European Association for the Study of the Liver recommends not ignoring mild, persistent elevations, as even mild elevations persisting beyond 6 months warrant thorough evaluation 2, 3
The American Gastroenterological Association recommends not attributing all elevations to fatty liver, and excluding other causes even when NAFLD is suspected 4, 5